Hemodialysis elimination rates and clearance of gentamicin and tobramycin
- PMID: 6703676
- PMCID: PMC185450
- DOI: 10.1128/AAC.25.1.128
Hemodialysis elimination rates and clearance of gentamicin and tobramycin
Abstract
The apparent hemodialyzer elimination rate constant and clearance for gentamicin and tobramycin were determined during 100 routine hemodialysis treatments in 49 patients. Three different dialyzers (CDAK 3500, CF 1211, and CF 1511), which vary in membrane composition, surface area, and thickness, were evaluated. The elimination rate constant in each patient was calculated from the slope of the log serum concentration-time curves. Two different elimination rate constants for each patient were derived, one during hemodialysis (KT) and one off hemodialysis (K). The hemodialyzer elimination rate constant (KD) for each dialyzer was calculated as the difference between these two values. The hemodialyzer clearance (Cd) was calculated by multiplying the hemodialyzer elimination rate constant by the volume of distribution of the patient. The KDS of gentamicin and tobramycin by the three dialyzers were significantly different. The gentamicin KD of the CDAK 3500 was lower than the values of the CF 1211 and CF 1511 (0.086 versus 0.123 versus 0.131 h-1, respectively). The Cd of the CDAK 3500 for gentamicin was also significantly lower than that of the CF 1511. Although the CdS of tobramycin for the CF 1211 and CF 1511 were 24 and 43% greater than that for the CDAK 3500, these differences were not statistically significant. The KD and Cd of tobramycin were greater than those of gentamicin for all three dialyzers. These data demonstrate that commonly used hemodialyzers vary markedly with respect to their elimination and clearance characteristics of gentamicin and tobramycin. Clinically, these observations may be helpful in designing the correct dose of gentamicin and tobramycin to achieve maximum drug safety and efficacy in hemodialysis patients.
Similar articles
-
Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers.Am J Kidney Dis. 1993 Aug;22(2):296-9. doi: 10.1016/s0272-6386(12)70321-9. Am J Kidney Dis. 1993. PMID: 8352256
-
Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis.Pediatr Pulmonol. 1985 Sep-Oct;1(5):238-43. doi: 10.1002/ppul.1950010504. Pediatr Pulmonol. 1985. PMID: 4069813
-
Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys.J Infect Dis. 1976 Jun;133(6):627-36. doi: 10.1093/infdis/133.6.627. J Infect Dis. 1976. PMID: 932490
-
Aspects of the pharmacology and toxicology of tobramycin in animals and humans.J Infect Dis. 1976 Aug;134 Suppl:S97-103. doi: 10.1093/infdis/134.supplement_1.s97. J Infect Dis. 1976. PMID: 787452 Review.
-
National Kidney Foundation report on dialyzer reuse. Task Force on Reuse of Dialyzers, Council on Dialysis, National Kidney Foundation.Am J Kidney Dis. 1997 Dec;30(6):859-71. doi: 10.1016/s0272-6386(97)90096-2. Am J Kidney Dis. 1997. PMID: 9398135 Review.
Cited by
-
Isepamicin disposition in subjects with various degrees of renal function.Antimicrob Agents Chemother. 1991 Nov;35(11):2382-7. doi: 10.1128/AAC.35.11.2382. Antimicrob Agents Chemother. 1991. PMID: 1804011 Free PMC article.
-
Bayesian pharmacokinetics of gentamicin in a haemodialysis population.Clin Pharmacokinet. 2004;43(3):205-10. doi: 10.2165/00003088-200443030-00004. Clin Pharmacokinet. 2004. PMID: 14871157
-
Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing.Clin J Am Soc Nephrol. 2008 Mar;3(2):355-61. doi: 10.2215/CJN.02920707. Epub 2008 Jan 30. Clin J Am Soc Nephrol. 2008. PMID: 18235142 Free PMC article.
-
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002. Clin Pharmacokinet. 1992. PMID: 1559311 Review.
-
Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.J Thorac Dis. 2018 May;10(5):3102-3118. doi: 10.21037/jtd.2018.05.11. J Thorac Dis. 2018. PMID: 29997980 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical